KCT0006101招募中未知
An Open Label, Single-Arm, Multi-center Phase Ib/II Study to Evaluate the Efficacy of Paclitaxel in Combination with Pembrolizumab and Olaparib as a Second Line Treatment in Immune Checkpoint Inhibitor-experienced Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 77
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1.Male/female participants who are at least 19 years of age with histologically confirmed diagnosis of advanced or metastatic gastric or GEJ adenocarcinoma.
- •2.A male participant must agree to use a contraception during the treatment period and for at least 120 days and refrain from donating sperm during this period.
- •3.A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: a) Not a woman of childbearing potential (WOCBP) OR b) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 180 days after the last dose of study treatment.
- •4.The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.
- •5.Have measurable or evaluable disease based on RECIST 1.1.
- •6.Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
- •7.Have adequate organ function as defined in Table 3.
- •8.Has life expectancy of at least 3 months.
- •9.Is able to swallow and retain orally administered medications.
- •10.Failed first-line trastuzumab treatment for HER2 positive patients.
- •11.Left ventricular ejection fraction (LVEF) =50% measured by multiple-gated acquisition scan (MUGA) or electrocardiogram (ECHO).
排除标准
- •1.A WOCBP who has a positive urine pregnancy test within 72 hours prior to allocation.
- •2.Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor.
- •3.Has received prior systemic anti-cancer therapy including investigational agents within 2 weeks prior to allocation.
- •4.Has received prior radiotherapy within 2 weeks of start of study treatment.
- •5.Has received a live vaccine within 30 days prior to the first dose of study drug.
- •6.Is currently participating in or has participated in a study of an investigational agent including trastuzumab or has used an investigational device within 4 weeks prior to the first dose of study treatment.
- •7.Has previously received olaparib or other PARP inhibitors.
- •8.Has a history of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or characteristics of MDS/AML.
- •9.Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
- •10.Has a known additional malignancy that is progressing or has required active treatment within the past 5 years.
- •11.Has known active CNS metastases and/or carcinomatous meningitis.
- •12.Has severe hypersensitivity (=Grade 3) to pembrolizumab and/or any of its excipients, PARP inhibitor and paclitaxel.
- •13.Has active autoimmune disease that has required systemic treatment in the past 2 years.
- •14.Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
- •15.Has an active infection requiring systemic therapy.
- •16.Has a known history of Human Immunodeficiency Virus (HIV).
- •17.Has an active of Hepatitis B or known active Hepatitis C virus infection.
- •18.Has an active TB (Bacillus Tuberculosis) with treatment.
- •19.May potentially influence the results of this trial, interfere with subject’s participation in overall duration of the study, or has history of or current evidence of conditions, treatment, or abnormal laboratory values that is deemed to be not in the best interests of the subject to participate in the trial in the opinion of treating investigator.
- •20.Has received more than 2nd lines of systemic chemotherapy.
- •21.Is mentally ill or has substance abuse disorder that may affect subject’s compliance with requirements of the study.
- •22.Is pregnant or breastfeeding, or is planning to become pregnant within the study period starting from screening visit to 120 days after the last dose of study treatment.
- •23.Is otherwise not appropriate to enroll in this study as determined by the investigator.
研究者
相似试验
已完成
不适用
A study to evaluate the Safety and Efficacy of Nivolumab in Combination with Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric CancerKCT0004186Yonsei University Health System, Severance Hospital62
已完成
不适用
Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a second-line therapy for recurrent / progressive gastric cancer with INCB054828 and paclitaxel a study to evaluate the safety and efficacy of combination therapy.KCT0003844Yonsei University Health System, Severance Hospital42
已完成
不适用
Phase Ib/II Study of M7824 and Paclitaxel Combination in Recurrent/Metastatic Gastric Cancer as a Second-line TreatmentKCT0006078Yonsei University Health System, Severance Hospital49
招募中
1 期
A Single-Arm, Open-Label, Multi-Centre, Phase Ib Study Evaluating the Safety and Preliminary Efficacy of AUTO1 in Pediatric Patients with CD19-Positive Relapsed/ Refractory (r/r) B cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B cell Non-Hodgkin Lymphoma (B NHL)B-cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL).MedDRA version: 21.0Level: LLTClassification code: 10000844Term: Acute lymphoblastic leukaemia Class: 10029104CTIS2023-506307-26-00Autolus Limited24
招募中
Unknown
A multicenter study to evaluate the safety and efficacy of T-DXd in combination with ramucirumab in patients with HER2 low mutations gastric or gastroesophageal junction (GEJ) adenocarcinomaKCT0008627Yonsei University Health System, Severance Hospital58